NCT00070499 2026-03-18
Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
108 trialsNCT00792948 2026-03-18
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02143414 2026-03-18
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04971226 2026-03-10
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
Phase 3 Active not recruiting
NCT00364286 2026-01-20
Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00254423 2026-01-15
Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00255346 2025-12-30
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03654768 2025-12-18
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
SWOG Cancer Research Network
Phase 2 Active not recruiting
NCT02883049 2025-11-26
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05198843 2025-10-03
Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT05192889 2025-09-22
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
St. Jude Children's Research Hospital
Phase 1/2 Active not recruiting
NCT02420717 2025-06-08
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00390793 2025-02-17
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01471106 2024-07-10
Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02954523 2024-07-05
Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
Georgetown University
Phase 1/2 Terminated
NCT04115059 2024-03-21
Dasatinib In Waldenström Macroglobulinemia
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT05286528 2023-10-27
Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
Pfizer
Completed
NCT00550615 2023-09-26
Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma
University of Nebraska
Phase 1/2 Completed
NCT02059265 2023-08-01
Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00700882 2023-07-03
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT01593254 2023-06-22
DASCERN
Bristol-Myers Squibb
Phase 2 Completed
NCT00529763 2023-05-08
Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects
Bristol-Myers Squibb
Phase 2 Completed
NCT02297139 2023-05-06
Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib
Bristol-Myers Squibb
Phase 2 Completed
NCT01306942 2023-03-30
Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients
Spanish Breast Cancer Research Group
Phase 1/2 Completed
NCT01850004 2022-11-03
DASFREE
Bristol-Myers Squibb
Phase 2 Completed
NCT00549848 2022-08-23
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 3 Completed
NCT03023046 2022-07-13
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
University of Washington
Phase 2 Completed
NCT04006847 2022-07-01
Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Milton S. Hershey Medical Center
Phase 1/2 Terminated
NCT02720185 2022-06-03
Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
University of Wisconsin, Madison
Phase 2 Terminated
NCT03041701 2022-04-14
Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01876953 2022-03-31
Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia
City of Hope Medical Center
Phase 1/2 Terminated
NCT00566618 2022-02-25
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01460160 2021-12-08
Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
Bristol-Myers Squibb
Phase 2 Completed
NCT01620216 2021-11-04
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT01441882 2021-04-08
Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia
OHSU Knight Cancer Institute
Phase 2 Completed
NCT02750514 2021-03-22
FRACTION-Lung
Bristol-Myers Squibb
Phase 2 Terminated
NCT01652976 2021-01-05
FOLFOX-D
University of Florida
Phase 2 Completed
NCT01999985 2020-11-27
Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT00780676 2020-09-03
Personalized Treatment Selection for Metastatic Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02428855 2020-07-31
Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma
Massachusetts General Hospital
Phase 2 Completed
NCT00720109 2020-04-13
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT02011945 2020-03-18
A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
Bristol-Myers Squibb
Phase 1 Completed
NCT00869401 2020-02-13
Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
NCT02819804 2020-02-11
Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Northwestern University
Phase 1 Terminated
NCT00036738 2020-01-29
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00892177 2019-10-21
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01876212 2019-08-22
Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
University of Pittsburgh
Phase 2 Completed
NCT00949988 2019-08-14
BMS-CA180105
University of California, San Diego
Phase 1/2 Terminated
NCT00820170 2019-08-13
Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00423735 2019-07-24
Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
Phase 2 Completed